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Abstract
Background: A previous study found that brain natriuretic peptide (BNP) inhibited inflammatory pain via activating
its receptor natriuretic peptide receptor A (NPRA) in nociceptive sensory neurons. A recent study found that
functional NPRA is expressed in almost all the trigeminal ganglion (TG) neurons at membrane level suggesting a
potentially important role for BNP in migraine pathophysiology.
Methods: An inflammatory pain model was produced by subcutaneous injection of BmK I, a sodium channel-
specific modulator from venom of Chinese scorpion Buthus martensi Karsch. Quantitative PCR, Western Blot, and
immunohistochemistry were used to detect mRNA and protein expression of BNP and NPRA in dorsal root
ganglion (DRG) and dorsal horn of spinal cord. Whole-cell patch clamping experiments were conducted to record
large-conductance Ca2+-activated K+ (BKCa) currents of membrane excitability of DRG neurons. Spontaneous and
evoked pain behaviors were examined.
Results: The mRNA and protein expression of BNP and NPRA was up-regulated in DRG and dorsal horn of spinal
cord after BmK I injection. The BNP and NPRA was preferentially expressed in small-sized DRG neurons among
which BNP was expressed in both CGRP-positive and IB4-positive neurons while NPRA was preferentially expressed
in CGRP-positive neurons. BNP increased the open probability of BKCa channels and suppressed the membrane
excitability of small-sized DRG neurons. Intrathecal injection of BNP significantly inhibited BmK-induced pain
behaviors including both spontaneous and evoked pain behaviors.
Conclusions: These results suggested that BNP might play an important role as an endogenous pain reliever in
BmK I-induced inflammatory pain condition. It is also suggested that BNP might play a similar role in other
pathophysiological pain conditions including migraine.
Background
Chronic pain is a common and serious health problem all
around the world. Chronic inflammatory pain resulted
from the tissue insult can last for months. The inflamma-
tory pain behaviors induced by venom of Chinese scorpion
Buthus martensi Karsch (BmK) include spontaneous pain,
ipsilateral thermal hypersensitivity, and bilateral mechanical
hypersensitivity in rats [1, 2]. The BmK venom producing
inflammatory pain contains various neurotoxins described
as specific modulators of voltage-gated sodium channels
(VGSCs) [3–5]. Among them, BmK I is a α-like neurotoxin
that slows down the inactivation of sodium channels
through binding on VGSC receptor site 3 [6–8]. Import-
antly, BmK I has been demonstrated to be the indispens-
able contributor for the inflammatory pain caused by the
BmK venom.
Natriuretic peptides (NPs) are a family of structurally re-
lated peptides derived from several genes, including atrial
natriuretic peptide (ANP), brain natriuretic peptide
(BNP), and C-type natriuretic peptide (CNP) in mammals.
NPs play their roles through binding to specific high affin-
ity receptors on the surface of target cells, including
NPRA, NPRB and NPRC [9, 10]. BNP, which was initially
identified in porcine brain [11], is considered to act on
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NPRA, a guanylyl cyclase receptor, and subsequently acti-
vates pGC to produce cGMP [12]. cGMP directly opens
cyclic nucleotide gated (CNG) channels, and also plays
vital physiological roles via activating protein kinase G
(PKG) pathway [13].
Accumulating evidences indicate that all NPs and their re-
ceptors are widely distributed in a variety of tissues [14–16].
In the central nervous system (CNS), functions of BNP and
NPRA range from modulating neuroprotection to synaptic
transmission [17]. A previous study found that BNP inhibited
the excitability of small dorsal root ganglion (DRG) neurons,
pain receptors in the peripheral nervous system, and inflam-
matory pain induced by CFA and formalin through activat-
ing the NPRA/PKG/BKCa channel pathway [18]. A recent
study found that functional NPRA is expressed in almost all
the trigeminal ganglion (TG) neurons at the membrane level
[19]. Chronic activation of NPRA by BNP down-regulated
the excitability of TG neurons.
In the present study, we investigated the role of BNP
in the BmK I-induced inflammatory pain. We found that
BmK I increased the expression of BNP and NPRA in
DRG and spinal cord. The increased expression in DRG
was preferentially in small-sized DRG neurons. BNP
increased BKCa currents and suppressed membrane
excitability of DRG neurons, and inhibited spontaneous
and evoked pain behaviors induced by BmK I.
Methods
Animals
Adult male Sprague–Dawley rats were provided by
Shanghai Experimental Animal Center, Chinese Academy
of Sciences. Rats weighing 220–250 g were used in the be-
havioral test, immunohistochemistry, Western Blot, and
qRT-PCR experiments while rats weighing 80–120 g were
used in electrophysiological experiments. Rats were
housed in a light/dark cycle of 12 h, at 21–23 °C stable
room temperature and 50 % humidity. All animal experi-
ments followed European Community guidelines for the
use of experimental animals and the policies issued by the
International Association for the Study of Pain [20].
Inflammatory pain model
The crude BmK venom was purchased from an individ-
ual scorpion culture farm in Henan Province, China.
BmK I was purified according to previously described
procedures [7]. BmK I (dissolved in sterile saline) was
intraplantarly (i.pl.) injected into the left side of rat hind
paw.
Preparation and administration of BNP
BNP was purchased from Sigma-Aldrich (St. Louis, MO,
USA). BNP was dissolved in saline. As described previ-
ously, 10 μl BNP were directly injected by lumbar punc-
ture at the L4-L5 spinal cord [21].
Behavioral tests
The dose-dependent and time-related effects of BmK I-
induced pain-related behaviors were investigated. The
rats were randomly divided into 4 groups: (1) rats with
i.pl. injection of 10 μg/50 μl BmK I in sterile saline (n =
7); (2) rats with i.pl. injection of 10 μg/50 μl BmK I in
sterile saline at 0.5 h after intrathecal (i.t.) injection of
sterile saline (n = 7); (3) rats with i.pl. injection of 10 μg/
50 μl BmK I at 0.5, 2, 3, 4 h after i.t. injection of 2 μg/
10 μl BNP (n = 7); (4) rats with i.pl. injection of 10 μg/
50 μl BmK I at 2 h after i.t. injection of 1,2,3 μg/10 μl
BNP (n = 3). After BmK I injection, pain-related behaviors
induced by BmK I were tested at different time points. For
the spontaneous pain, rats were continuously observed for
2 h after BmK I injection. And then, the tests for the de-
velopmental time window of thermal hypersensitivity were
performed at 4, 8 h, and then at 1, 2, 3, 5, 7, and 10 days
after injection of BmK I. The tests of the developmental
time window of mechanical hypersensitivity were evalu-
ated at 2, 4, 8 h, and then at 1, 2, 3, 5, 7, and 10 days after
injection of BmK I. The measurement of rat spontaneous
nociceptive responses, paw withdrawal mechanical thresh-
old (PWMT) and paw withdrawal thermal latency
(PWTL) of rats described by our previous report [2].
Real-time quantitative polymerase chain reaction
Total RNA was isolated from ipsilateral and Contralateral
L4-L5 spinal cord and DRG of adult male rats (at each time
course, n= 3) with Total RNA Extractor (Trizol) (Sangon
Biotech, Shanghai, China), then reverse-transcribed with
Prime-Script®RT Master Mix (TaKaRa, Dalian, China), ac-
cording to the manufacturer’s protocol. Primer sequences
targeted to BNP, NPRA, GAPDH and β-actin were designed
by Primer Premier 6.0 software, with sequences respectively
were as follows (Table 1). All primers were synthesized by
Invitrogen (Shanghai, China). Quantitative PCR was per-
formed in SYBR® Premix Ex TaqTM (TaKaRa, Dalian,
China), using CFX96 Touch™ Real-Time PCR Detection Sys-
tem (Bio-Rad). The BNP and NPRA subtypes mRNA was
normalized to the average of GAPDH and β-actin mRNA
level. Data were analyzed using the delta-delta Ct method.
Table 1 Sequences of primers
Primer name Primer sequences (5′-3′)
BNP-S -AAGGACCAAGGCCCTACAA-
BNP-A -CGGTCTATCTTCTGCCCAAA-
NPRA-S -AGGAGATGGGCAGGACAGGA-
NPRA-A -TCAGGATTATCAGGCTCTTTGT-
β-actin-S -ACTATCGGCAATGAGCGGTTCC-
β-actin-A -AGCACTGTGTTGGCATAGAGGTC-
GAPDH-S -CAAGTTCAACGGCACAGTCA-
GAPDH-A - CCATTTGATGTTAGCGGGAT-
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Western blotting
At different time points (2 h, 8 h, 1 day, 2 days, 5 days,
7 days) after i.pl. BmK I injection, the rats were anesthe-
tized by intraperitoneal injection of pentobarbital sodium
(60 mg/kg). The L4-L5 spinal cord and DRG were rapidly
removed, and stored at −80 °C. Their protein lapping liq-
uids were obtained by homogenization in ice-cold RIPA
Lysis Buffer (Beyotime, Shanghai, China). The supernatant
was collected after centrifugation at 12000 r/min for
15 min. Protein concentration was measured using BCA
Protein Assay Kit (Biotech Well, Shanghai, China). SDS-
PAGE Sample Loading Buffer was mixed into the super-
natant by proportion and the mixture was bathed for
5 min at boiling water. Protein samples (20 μl) were con-
centrated on 6 % SDS-PAGE concentrated gels and sepa-
rated on 10 % (for macromolecular protein) or 15 % (for
small molecular protein) SDS-PAGE separation gels and
blotted on a polyvinylidene fluoride membrane (Merck
Millipore, Germany). The membranes were blocked in
nonfat milk solution for 2 h, and then incubated overnight
at 4 °C with primary antibodies solution: goat polyclonal
anti-BNP (1:200; Santa Cruz, CA, USA), rabbit polyclonal
anti-NPRA (1:300, Abcam, MA, USA), mouse polyclonal
anti-β-actin (1:500; Santa Cruz, CA). Next day, the mem-
branes were incubated with primary antibodies solution for
2 h at room temperature (RT) and washed using PBST (5-
10 min) for three times, then incubated for 1.5 h at RT with
secondary antibodies solution: goat anti-rabbit IgG(H+ L)
HRP(1:12 000; Kangchen, CA), rabbit anti-goat IgG(H+ L)
HRP(1:10 000; Kangchen, CA), goat anti-mouse IgG(H + L)
HRP(1:10 000; Kangchen, CA). The blots were ignited in
ECL reagent (Merck Millipore, Germany), and then devel-
oped in fully automatic chemiluminescence image analysis
system (Tanon, Shanghai, China). Gel image system 1D
Analysis Software(Tanon) was used for their densitometric
quantification. The standardization ratio of BNP or NPRA
to β-actin band densitometric data was used to calculate
the change of the expression.
Immunohistochemistry
Two days after i.pl. BmK I injection, the adult rats were
anesthetized by pentobarbital sodium, then perfused
with sterile saline and 4 % paraformaldehyde in 0.1 mol/
L phosphate buffer (PB). The rat L4-L5 lumbar spinal
cord and DRG tissues was post-fixed and cryoprotected
in 20 % sucrose 0.1 mol/L PB solution, then moved into
the 30 % sucrose solution. Tissue transverse frozen
sections (20 μm thick) were cut on CM1900 freezing
microtome (Leica, Germany) and stored at −20 °C. Fro-
zen sections were in the wet air for 0.5 h and were incu-
bated with 5 % goat serum (in PBS) for 2 h at RT
followed by incubation overnight at 4 °C with primary
antibodies diluent (contain 0.3 % Triton X-100): goat
polyclonal anti-BNP (1:50; Santa Cruz, CA, USA), rabbit
polyclonal anti-NPRA (1:100; Abcam, MA, USA), mouse
monoclonal anti-NeuN (1:500; Millipore Bioscience
Research Reagents, DA, GER), Mouse monoclonal to
calcitionin gene related peptide (CGRP) (1:100; Abcam,
MA, USA), fluorescein-conjugated isolectin-B4(IB4)
(1:400; Sigma), Mouse monoclonal Anti-Neurofilament
200 (NF200) (1:800; Sigma). Before incubation with sec-
ondary antibodies, the sections were washed using PBS
(5-10 min) for three times. After 2 h of incubation with
secondary antibodies: goat anti-rabbit IgG, Cy3 conjugate
(1:400; Merck Millipore), rabbit anti-goat IgG, Cy3 conju-
gate (1:100; Biotech Well), donkey anti-mouse IgG Fluores-
cein (FITC) conjugate (1:200; Jackson Immunoresearch),
the sections were washed using PBS (5-10 min) for three
times. Digital images were captured from laser scanning
confocal microscope (Leica, Germany) and then merged by
Image J software.
Electrophysiology
The rats were anesthetized with ether and decapi-
tated. DRGs were dissected from the L4-L5 lumbar
region. Neurons were acutely isolated from DRGs
with 1 mg/ml collagenase type 1A, 0.6 mg/ml trypsin
type I, in D-Hanks at 37 °C for 30 min. Single cells
were dissociated mechanically with a series of fire-
polished Pasteur pipettes, and plated on glass slides
covered with Poly-D-Lysine, then placed into dishes.
The cells were cultured for 2 h in Dulbecco’s modi-
fied Eagle medium (DMEM F12; Gibco, Invitrogen,
Grand Island, NY, USA). Culture dishes were incu-
bated at 37 °C in a humidified atmosphere containing
5 % CO2. Patch clamp was performed within 0-10 h
after culturing. All of the recordings were made from
small-diameter (<25 μm) DRG neurons. External
solution (ECS) contained (mM): 5 KCl, 150 NaCl, 2
CaCl2, 1.5 MgCl2, 10 HEPES, and 10 glucose, pH 7.4.
2, 1.75, 1.5 and 2.0 mM CaCl2 was replaced by the
same concentration of MgCl2 to prepare ECS con-
taining 0, 0.25, 0.5 and 1 mM Ca2+. The pipette
solution contained (mM): 140 KCl, 1 MgCl2, 2 CaCl2,
5 EGTA, 10 HEPES, 2 Na-ATP, and 0.3 Na-GTP,
pH 7.3. ECS were saturated with O2 before using.
BKCa channel blocker: iberiotoxin (IBTX). Whole-cell
path clamping experiments were performed using an
EPC-10 amplifier (HEKA eletronik, Germany) at
room temperature. Patch pipettes were fabricated
from glass capillary tubes by PP-830 Puller
(Narishige, Japan) with the resistance of 3–5 MΩ.
Data acquisition and stimulation protocols were con-
trolled by Pulse/PusleFit 10.0 software (HEKA Elektronik).
Before “breakthrough” with additional suction, seal
resistance was more than 1GΩ. After whole-cell
mode was established, input resistance was larger
than 200 MΩ.
Li et al. The Journal of Headache and Pain  (2016) 17:90 Page 3 of 15
Statistical analysis
The data were analyzed with GraphPad prism 5.0
Software and Origin 8.5 Software. All data were pre-
sented as means ± SEM (standard error). Statistical ana-
lysis of the data was performed using one-way ANOVA
followed by Fisher’s PLSD test, two-way ANOVA
followed by Boferroni or unpaired Student’s t-test. Values
were considered as statistically significant at P < 0.05.
Results
Up-regulation of BNP and NPRA in DRG and spinal cord
in the BmK I-induced pain models
The mRNA expression of BNP and NPRA before and
after BmK I injection was firstly examined in DRG and
spinal cord using real-time, quantitative PCR technique.
As shown in Fig. 1, BmK I caused significant increase in
mRNA expression of BNP (Fig. 1a & c) and NPRA
(Fig. 1b & d) at multiple time points after injection in
ipsilateral DRG and spinal cord. The mRNA expression
of BNP and NPRA was not significantly changed at any
time points after BmK I injection in either contralateral
DRG or spinal cord. The time course of BmK I increas-
ing mRNA expression of BNP and NPRA appeared dif-
ferent in DRG (Fig. 1a & b). The expression of BNP was
increased by about 2.5 times at 2 h and 8 h after BmK I
injection compared to control. At day1, the expression
of BNP peaked at a level about 5 times higher than con-
trol. At day2 and day5, the peaked expression reduced to
a level similar to 2 h and 8 h. In contrast to this
transient-peak pattern of BNP, the expression of NPRA
increased gradually after BmK I injection and reached
peak at day5. Compared to DRG, the time course of
BmK I-increased expression of BNP and NPRA was
similar in spinal cord (Fig. 1c & d). Both BNP and
NPRA showed a peak expression at day2 after BmK I
injection.
The effects of BmK I on the expression of BNP and
NPRA was further studies at protein level using Western
Blotting technique. As shown in Fig. 2, BmK I signifi-
cantly increased protein expression of BNP (Fig. 2a & c)
and NPRA (Fig. 2b & d) at some time points after injec-
tion in ipsilateral DRG and spinal cord. The protein
expression of BNP and NPRA was not significantly
changed at any time points after BmK I injection in
either contralateral DRG or spinal cord. The time course
of BmK I increasing protein expression of BNP and
NPRA appeared different in DRG (Fig. 2a & b). The pro-
tein expression of BNP was peaked at day5 while the
expression of NPRA was peaked at day1. In spinal cord,
the BmK I-caused increase in protein expression was
peaked at day2 after injection for both BNP and NPRA
(Fig. 2c & d).
Fig. 1 The mRNA expression of BNP and NPRA in DRG and spinal cord at different time points after BmK I injection. a: The mRNA expression
level of BNP in bilateral sides of L4-L5 DRG. b: The mRNA expression level of NPRA in bilateral sides of L4-L5 DRG. c: The mRNA expression level
of BNP in bilateral sides of L4-L5 spinal cord. d: The mRNA expression level of NPRA in bilateral sides of L4-L5 spinal cord. *P < 0.05, **P < 0.01,
***P < 0.001 compared with control groups (n = 3). Error bars indicated S.E.M
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Fig. 2 Western blot analysis showed the protein expression of BNP and NPRA in DRG and spinal cord at different time points after BmK I
injection. a: The protein expression of BNP in bilateral sides of L4-L5 DRG. b: The protein expression of NPRA in bilateral sides of L4-L5 DRG. c: The
protein expression of BNP in bilateral sides of L4-L5 spinal cord. d: The protein expression of NPRA in bilateral sides of L4-L5 spinal cord. *P < 0.05,
**P < 0.01, ***P < 0.001 compared with control groups (n = 3). Error bars indicated S.E.M
Fig. 3 Representative microphotographs showed the location and expression of BNP and NPRA in NF200-positive DRG neurons. Almost all
immunofluorescence staining for BNP and NPRA (a, d) was not co-localized (c, f) with NF200 (b, e) (n = 3). Scale bar, 50 μm
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Fig. 4 (See legend on next page.)
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To study the BmK I-increased expression of BNP and
NPRA in different neuronal populations, immunohisto-
chemical experiments were conducted on tissue slices of
DRG. Double staining of NF200 (marker for myelinated,
large fiber/soma in DRG) and BNP or NPRA was first
examined. As showed in Fig. 3, both BNP and NPRA
were preferentially expressed in the small DRG neurons
while NF200 was preferentially expressed in the large
DRG neurons. To further study neuronal subpopulations
in small-sized DRG neurons, staining markers CGRP
and IB4 were used to label the peptidergic neurons and
non-peptidergic neurons, respectively. It was found that
BNP was expressed in both CGRP-positive and IB4-
positive neurons while NPRA was preferentially
expressed in CGRP-positive neurons (Fig. 4a-c and g-i,
Fig. 5a-c and g-i). Two days after BmK I injection, the
immunostaining of BNP was significantly increased in
both CGRP-positive and IB4-positive neuronal subpopu-
lations (Fig. 4m). On the other hand, the immunostain-
ing of NPRA was selectively increased in the CGRP-
positive neurons compared to IB4-positive neurons
(Fig. 5m).
As shown in Fig. 6, BNP and NPRA were double-
immunofluorescent with a neuron marker (NeuN) in
spinal cord. It was found that the immunofluorescence
staining of both BNP and NPRA was increased in ipsilat-
eral but not in contralateral spinal cord at 2 days after
i.pl. BmK I injection.
Elevating the open probability of BKCa channels and
suppressing excitability of small DRG neurons by BNP
A voltage stimulation depolarizing from −50 to 90 mV
(0.2 s duration) was used to trigger outward currents in
small DRG neurons. A selective BKCa channel blocker
IBTX (100 nM) was used to block BKCa currents (Fig. 7a
& b). The outward currents blocked by 100 nM IBTX
were defined as BKCa currents. To test the effects of
BNP on the BKCa currents, BNP (100 ng/ml) were pre-
treated for 3 h in culture medium. Acute application of
BNP at the same concentration for 10 min did not
change BKCa currents (Fig. 7c). At 0 extracellular Ca
2+
condition, the BKCa currents were not activated in the
either absence or presence of BNP (100 ng/ml) (Fig. 7a
& d). Increasing extracellular Ca2+ from 0.25 to 2 mM
gradually increased the density of the BKCa currents in
the either absence or presence of BNP (100 ng/ml)
(Fig. 7b & d). Compared to control, 100 ng/ml BNP
significantly increased the density of BKCa currents at
0.5, 1, and 2 mM extracellular Ca2+ conditions (Fig. 7d,
n = 7). The activation curve of the BKCa currents was
shifted by BNP positively. The midpoint of activation
(V1/2) was significantly rightward shifted from −2.38 ±
1.60 to 61.39 ± 4.95 and the slope factor (km) was in-
creased from 15.12 ± 1.47 to 23.02 ± 3.27 (Fig. 7e). The
increasing effects of BNP on BKCa current density of
small DRG neurons were similar at 1 or 2 days after
BmK I injection compared to pre-injection control
(Fig. 7f, n = 5). However, BNP caused a larger increase in
BKCa current density at 5 days after BmK I injection
compared to pre-injection, 1 day and 2 days after BmK I
injection (Fig. 7f ).
Current-clamp recordings were employed to deter-
mine the effect of BNP on the excitability of DRG neu-
rons. A depolarizing current (1 s duration, 200 pA) was
injected into small DRG neurons to trigger action poten-
tials. The effects of 10 min ECS, 10 min BNP, pretreat-
ment of BNP for 3 h, and pretreatment of BNP for 3 h
+ IBTX were examined in the absence (“before treat-
ment”, Fig. 8a-left) and presence of treatments (“after
treatment”, Fig. 8a-right). Application of BNP signifi-
cantly lowered the number of action potentials (from
15.4 ± 1.2 to 12.3 ± 1.4; n = 12). The decreasing effect of
BNP on action potential number was prevented by pre-
treatment of 100 n M IBTX (Fig. 8a). The ratio of the
action potential halfwidth (after treatment vs before
treatment) was not altered by application of BNP for
10 min (1.060 ± 0.042; n = 12). However, pretreatment of
BNP for 3 h significantly increased the ratio to 2.002 ±
0.078 (n = 12) compared to ECS (1.031 ± 0.042; n = 12).
The increasing effect of BNP on ratio halfwidth was pre-
vented by pretreatment of 100 n M IBTX (0.992 ± 0.034;
n = 12) (Fig. 8b).
Inhibition of BNP on BmK I-induced inflammatory pain re-
lated behaviors
The effects of intrathecal injection of BNP on BmK I-
induced pain behaviors were studied. Both spontaneous
pain behaviors and evoked pain behaviors were studied.
The spontaneous pain behaviors were studied in the first
two hours after BmK I injection while the evoked pain
behaviors were studied from 4 h to 10 days after BmK I
injection. The evoked pain behaviors were not studied
within the 4 h after BmK I injection to avoid the over-
lapping with the spontaneous pain behaviors.
(See figure on previous page.)
Fig. 4 Representative microphotographs showed the location and expression of BNP in CGRP-positive and IB4-positive small DRG neurons.
Immunofluorescene staining for BNP (a, d) and CGRP (b, e) were co-localized (c, f) in control (a-c) at 2 days after i.pl. BmK I injection
(d-f). Immunofluorescene staining for BNP (g, j) and IB4 (h, k) were co-localized (i, l) in control (g-i) at 2 days after i.pl. BmK I injection
(j-i). m, ratio of CGRP-positive and IB4-positive small DRG neurons co-localized with BNP between control group and the group of 2 days
after i.pl. BmK I injection. Scale bar, 50 μm
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Fig. 5 (See legend on next page.)
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Intrathecal injection of BNP significantly inhibited
the spontaneous pain behaviors induced by subcutaneous
injection of BmK I. As shown in Fig. 9a and Fig. 9c, intra-
thecal injection of BNP 2 h before intraplantar BmK I in-
jection significantly inhibited flinching from control value
of 1543 ± 21 to 1267 ± 21.9 (p < 0.001), 1088 ± 14.5 (p <
0.001) and 1198 ± 12.3 (p < 0.001) for 1ug, 2ug and 3ug of
BNP, respectively; n = 3 rats/group). To study time course
of intrathecal BNP on the spontaneous pain behaviors
produced by BmK I, BNP were injected intrathecally at
0.5 h, 2 h, 3 h, 4 h before subcutaneous injection of BmK
I. Spontaneous pain behaviors including flinching, parox-
ysmal, lifting and licking of rats were tested. As shown in
Fig. 9b, d-f, BNP significantly inhibited the number of
flinching and paroxysmal behaviors, and the duration of
lifting and licking at 2–4 h before BmK I injection. The
peak inhibition occurred at 3 h before BmK I injection for
the spontaneous pain behaviors.
In addition to the acute spontaneous pain behaviors,
intrathecal injection of BNP significantly inhibited the
evoked pain behaviors over the time course from 4 h
to 10 days after BmK I injection. As shown in
Fig. 9g-i, intrathecal BNP significantly increased the
threshold and shortened the time course of paw with-
drawal for ipsilateral and contralateral mechanical
stimulation, and for ipsilateral thermal stimulation.
Paw withdrawal threshold for contralateral thermal
stimulation was not significantly changed by BmK I
injection in the absence or presence of intrathecal
BNP (Fig. 9j).
Discussion
This study showed that BNP and NPRA were expressed in
small DRG and spinal cord neurons, and were upregulated
after i.pl. BmK I injection. BNP was expressed in both
CGRP-positive and IB4-positive neurons while NPRA was
preferentially expressed in CGRP-positive neurons in
DRG. In vitro patch clamping experiments found that
BNP suppressed the membrane excitability through
increasing the open probability of the BKca currents. Fur-
thermore, intrathecal injection of BNP significantly inhib-
ited BmK I-induced nociceptive responses (Fig. 10).
Therefore, BNP secreted from nociceptive afferent neu-
rons might be an endogenous analgesic molecule for BmK
I-induced inflammatory pain. Considering the functional
expression of BNP/NPRA signal system in both DRG and
TG neurons, the activation of BNP signaling pathway
might have a broad prospect in recovering chronic pain
conditions including somatic pain and migraine [22–24].
(See figure on previous page.)
Fig. 5 Representative microphotographs showed the location and expression of NPRA in CGRP-positive and IB4-positive small DRG neurons.
Immunofluorescene staining for NPRA (a, d) and CGRP (b, e) were co-localized (c, f) in control (a-c) at 2 days after i.pl. BmK I injection
(d-f). Immunofluorescene staining for NPRA (g, j) and IB4 (h, k) were co-localized (i, l) in control (g-i) at 2 days after i.pl. BmK I injection
(j-i). m, Ratio of CGRP-positive and IB4-positive small DRG neurons co-localized with NPRA between control group and the group of 2 days
after i.pl. BmK I injection. Scale bar, 50 μm
Fig. 6 Representative microphotographs showed the location and expression of BNP and NPRA in NeuN-positive spinal cord neurons.
Immunofluorescene staining for BNP (a, d) and NeuN (b, e) were co-localized (c, f) in control (a-c) at 2 days after i.pl. BmK I injection
(d-f). Immunofluorescene staining for NPRA (g, j) and NeuN (h, k) were co-localized (i, l) in control (g-i) at 2 days after i.pl. BmK I injection (j-i). Scale
bar, 100 μm
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Fig. 7 BNP increased the open probability of BKCa channels. a: An outward current in small DRG neurons were induced by a voltage ramp from
−60 to 100 mV (0.2 s duration) in whole-cell voltage-clamp configuration. In Ca2+-free ECS BNP did not affect the current, IbTX did not change
the current significantly either. b: In small DRG neurons incubated in ECS with 1 mM Ca2+, the current was elevated by pretreatment of BNP
(100 ng/ml) for more than 2 h and was inhibited by BKCa channel inhibitor IbTX (100 nM). c: In small DRG neurons incubated in ECS with 1 mM
Ca2+, BKCa current was elevated by pretreated with BNP (100 ng/ml) for 3 h (n = 7), but not by bath-applied BNP (100 ng/ml) for 10 min (n = 6).
d: BKCa current was induced in small DRG neurons incubated in ECS with 0.5, 1 or 2 mM Ca
2+, and this current was increased by pretreatment of
BNP for 3 h (p < 0.01, n = 7 for 0.5 mM Ca2+ at 90 mV; p < 0.001, n = 7 for 1, 2 mM Ca2+ at 90 mV). In the presence of 0 or 0.25 mM extracellular
Ca2+, BKCa current was not induced and BNP did not have effect (n = 7 neurons/group). BKCa current was calculated as the difference between
total current and IBTX-resistant current, and was normalized to the cell membrane capacitance. e: G(V) relationship indicated that treatment of
BNP for 10 min did not enhance the activation of BKCa currents which was significantly rightward shifted after treatment of BNP for 3 h. f: 1 day,
2 days and 5 days after i.pl. BmK I injection, BKCa current density of small DRG neurons were elevated significantly compared with control rats.
**p < 0.01 and ***p < 0.001 versus control. Error bars indicated SEM
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The cGMP/PKG signaling pathway was involved in
inhibition of BNP on inflammatory pain
Most of neuropeptide-induced presynaptic inhibition
were mediated by G-protein-coupled receptors [25],
whereas NPRA was a guanylyl cyclase and did not bind
to G-protein. This might represent a novel mechanism
for regulating nociceptive afferent transmission. G-
protein-coupled receptor mediated signaling pathway
was thought to be a rapid response. However, NPRA
and receptor tyrosine kinase (RTK) were both enzyme-
linked receptors, which can attribute to a slow response.
There were many converted steps in signaling via RTK,
and some of them were much slower [26]. Similar to
this, signaling via NPRA might be very slow. The results
of our behavior test confirmed that the inhibition of
BNP in the inflammation pain was slow.
Activation of NPRA resulted in addition of cGMP/
PKG signaling [18]. The NPRA-mediated cGMP could
be elevated by different phosphodiesterase inhibitors
[27]. Coordinately, inhibition of cGMP degradation
reduces inflammatory pain induced by formalin after
intrathecal injection of the phosphodiesterase five inhibi-
tor sildenafil [28, 29]. Thus, the nociceptive afferent
transmission might be inhibited by BNP that raised
intracellular concentration of cGMP.
Just as the expression of NPRA, the PKG type I (cGKI)
was expressed in small DRG neurons and their afferent
neurons in the dorsal spinal cord [30]. Cysteine-rich
protein 2 (CRP2), a downstream effector of the cGKI,
was also expressed in cGKI-containing afferent neurons
in the spinal dorsal horn. Nociceptive response of CRP2-
knockout mice was elevated in inflammatory pain
model, which indicated that CRP2 contributed to inhib-
ition in pain transmission [31]. Therefore, the PKG sig-
naling pathway might negatively regulating nociceptive
afferent transmission.
DRG excitability was reduced by BNP via enhancing the
current of BKCa channels
The open probability of BKCa channel was enhanced
after activating NPRA/cGMP/PKG signaling pathway,
and the cell membrane was hyperpolarized through
phosphorylation of BKCa channel [32–34]. Specifically,
cGMP activated the activity of PKG, and then phosphor-
ylated BKCa channel at Ser1134 to regulate BKCa channel
activity [35]. The suppression induced by BNP was
blocked after treated with IBTX, a BKCa channel blocker,
indicated that BKCa channel was downstream of activat-
ing NPRA/cGMP/PKG signaling pathway. Activation of
NPRA increased intracellular cGMP level by stimulating
particulate GC, leading to calcium release from intracel-
lular store through a ryanodine-sensitive pathway [36].
After calcium releasing from intracellular store, calcium
was compensated via store-operated channels (SOC)
[37, 38]. Activation of SOC caused calcium influx and
additional increase in intracellular calcium, resulting in
an increase in BKCa current density and reduction in
DRG excitability.
Fig. 8 BNP reduced the excitability of small DRG neurons. a: The
representative action potentials triggered by depolarizing current
stimulation (1 s duration; 200 pA) in the absence (before treatment)
and presence (after treatment) of treatments including extracellular
solution condition (ECS), 10 min BNP, and 3 h pretreatment of BNP
without or with IBTX, respectively. b: The ratio of action potential
halfwidth in small DRG neurons in the presence (after treatment) vs.
absence (before treatment) of treatments. The action potential
halfwidth was measured from the first action potential triggered by
current injection. ***p < 0.001, treatment versus control. Error bars
indicated S.E.M
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Fig. 9 (See legend on next page.)
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Stimulation of BNP negatively regulated inflammation
pain
The current studies found that the mRNA and protein
expression of BNP and NPRA were elevated in small
DRG and spinal cord neurons following BmK I injection.
It was previously found that subcutaneous injection of
BmK I caused release of various biologically active
signaling molecules including proinflammation cytokines
and brain-derived neurotrophic factor [39–41]. These
findings suggest that some of the molecules stimulated
by BmK I might activate and cause secretion of BNP
from nociceptive afferent neurons resulting in an inhibi-
tory effect on the inflammatory pain.
Three doses of BNP were used to examine the effects
of BNP on spontaneous flinching (Fig. 9a & c). Although
the inhibitory effect of BNP was increased from 1 ug to
2 ug, but was almost unchanged when the dose was
further increased to 3 ug. We suspected that it could be
either the effects of BNP was saturated at 2 ug or a
reversing effect developed at 3 ug of BNP. Considering
the 3 ug BNP caused a smaller inhibition compared to 2
ug BNP (Fig. 9c), the latter possibility could be more
likely to be true.
Previously we have reported that BmK I induced a
mirror-image mechanical hypersensitivity where injec-
tion of BmK I at one side of hind paws caused mech-
anical hypersensitivity on both sides of hind paws. In
the current study, we found that BmK I selectively
up-regulated the expresion of BNP and NPRA at the
ipsilateral side but not at the contralateral side. Simi-
larly, intrathecal BNP selectively suppressed the spon-
taneous and evoked pain behaviors at the ipsilateral
side of rats. These results suggested that BNP might
not involve in the contralateral side of the mirror-
image mechanical hypersensitivity induced by BmK I.
BNP played a role in the relevant relation between pain
and itch
The present results showed that the increased expres-
sion of BNP and NPRA were increased and that the
increased expression might inhibit the pain response
after peripheral inflammation. It has been reported that
BNP was involved in the itch transmission in spinal
cord. BNP can activate spinal NPRA-expressing neurons
which then release gastrin releasing peptide (GRP). The
released GRP subsequently activate GRP receptor-
expressing neurons to relay itch information from the
periphery to the brain [42]. It is well know that when
pain is relieved during tissue healing, itch appears. The
results in the current study suggest that the increased
BNP and NPRA might be involve in both pain-relieving
and itch following tissue insult.
Conclusion
BNP and its receptor NPRA were expressed in small
DRG neurons and spinal cords neurons of rats. BNP
and NPRA were elevated after peripheral tissue
inflammation induced by BmK I. Furthermore, intra-
thecal application of BNP suppressed the excitability
of small DRG neurons and alleviated inflammatory
pain by activation of BNP signaling pathway. Based
on these results, we conclude that BNP and NPRA
might serve as endogenous pain-relieving signal sys-
tem in BmK I-induced inflammatory pain. Future
studies will determine whether BNP/NPRA system
plays a role in other pathophysiological pain condi-
tions including migraine.
(See figure on previous page.)
Fig. 9 BNP (i.t.) suppressed BmK I-induced inflammatory pain-related behaviors. a: Rat flinch behavior was attenuated by pretreatment of 10 μl
saline or BNP(1, 2 or 3 μg in saline) at 2 h before BmK I administration. b: Rat flinch behavior was attenuated by pretreatment of 10 μl saline or
BNP(2 μg in saline) at 0.5, 2, 3, 4 h before BmK I administration. c: Suppression of total number of the rat paw flinches by 10 μl saline or BNP(1, 2
or 3 μg in saline) during 2 h after BmK I injection. d: Suppression of total number of the rat paw flinches by 10 μl saline or BNP(2 μg in saline)
during 2 h after BmK I injection. e: Suppression of total number of paroxysmal pain-like behaviors by 10 μl saline or BNP(2 μg in saline) during
2 h after i.pl. BmK I injection. f: Suppression of duration of lifting and licking behaviorsby 10 μl saline or BNP(2 μg in saline) during 2 h after i.pl.
BmK I injection. Ipsilateral mechanical hyperalgesia (g), contralateral mechanical hyperalgesia (h) and ipsilateral thermal hyperalgesia (i) were
suppressed by 10 μl saline or BNP(2 μg in saline) pretreatment for 0.5, 2, 3, 4 h. j: There was no difference of conltralateral basal thermal latency
among five groups. Rat hindpaw injected with BmK I was considered as ipsilateral side, and the other side was named as contralateral side. All
data were showed as mean ± S.E.M. (a, c: n = 3; b, d-j: n = 7). *P < 0.05, **P < 0.01, ***P < 0.001, #P < 0.05, ##P < 0.01, ###P < 0.001, compared with
BmK I + saline group
Fig. 10 Flow chart of BNP signaling pathway induced by BmK I
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